MCID: NNT008
MIFTS: 40

Neonatal Abstinence Syndrome

Categories: Respiratory diseases, Mental diseases

Aliases & Classifications for Neonatal Abstinence Syndrome

Summaries for Neonatal Abstinence Syndrome

Disease Ontology : 12 A withdrawal disorder that is characterized by a group of problems that occur in a newborn who was exposed to addictive illegal or prescription drugs while in the mother's womb or postnatally following the discontinuance of drug treatment.

MalaCards based summary : Neonatal Abstinence Syndrome, also known as drug withdrawal syndrome in newborn, is related to drug dependence and chronic pain. An important gene associated with Neonatal Abstinence Syndrome is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways is Interleukin-4 and 13 signaling. The drugs Clonidine and Loperamide have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and heart, and related phenotypes are behavior/neurological and integument

Related Diseases for Neonatal Abstinence Syndrome

Graphical network of the top 20 diseases related to Neonatal Abstinence Syndrome:



Diseases related to Neonatal Abstinence Syndrome

Symptoms & Phenotypes for Neonatal Abstinence Syndrome

MGI Mouse Phenotypes related to Neonatal Abstinence Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.35 COMT NAGS OPRD1 OPRK1 OPRM1
2 integument MP:0010771 8.92 NAGS OPRD1 OPRK1 OPRM1

Drugs & Therapeutics for Neonatal Abstinence Syndrome

Drugs for Neonatal Abstinence Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1 4205-90-7 2803
2
Loperamide Approved Phase 4 53179-11-6 3955
3
Phenobarbital Approved, Investigational Phase 4,Phase 3 50-06-6 4763
4
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
5
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1 76-99-3 4095
6
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
7
Opium Approved, Illicit Phase 4 8008-60-4
8
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
10 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
11 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
12 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
14 Adrenergic Agents Phase 4,Phase 3,Phase 2
15 Adrenergic Agonists Phase 4,Phase 3,Phase 2
16 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2
17 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
18 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1
19 GABA Agents Phase 4,Phase 3
20 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
21 GABA Modulators Phase 4,Phase 3
22 Sympatholytics Phase 4,Phase 3,Phase 2
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1
26 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3
27 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Hypnotics and Sedatives Phase 4,Phase 3
30 Anticonvulsants Phase 4,Phase 3
31 Antidiarrheals Phase 4
32 Antihypertensive Agents Phase 4,Phase 3,Phase 2
33 Excitatory Amino Acid Antagonists Phase 4,Phase 3
34 Excitatory Amino Acids Phase 4,Phase 3
35 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Opium Poppy Nutraceutical Phase 4
38
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
39
Cocaine Approved, Illicit Phase 2, Phase 3 50-36-2 446220 5760
40
Chlorpromazine Approved, Investigational, Vet_approved Phase 3 50-53-3 2726
41
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 52485-79-7 644073 40400
42
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 657311 5754
43 Narcotic Antagonists Phase 3,Phase 2,Phase 1
44 Tranquilizing Agents Phase 3,Phase 1,Phase 2
45 Dopamine Agents Phase 3
46 Dopamine Antagonists Phase 3
47 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
48 Antiemetics Phase 3,Phase 1,Phase 2
49 Psychotropic Drugs Phase 3,Phase 1,Phase 2
50 Antipsychotic Agents Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show all 44)

# Name Status NCT ID Phase Drugs
1 Treatment of Neonatal Abstinence Syndrome Completed NCT01723722 Phase 4 Methadone;Diluted Deodorized Tincture of Opium
2 NAS Treatment - Opiate Versus Non-Opiate Completed NCT01734551 Phase 4 Morphine;Clonidine
3 Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal Completed NCT01804075 Phase 4 Methadone;Morphine
4 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Recruiting NCT02851303 Phase 4 Morphine;Methadone
5 Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy Not yet recruiting NCT03092011 Phase 4 Clonidine;Morphine Sulfate
6 Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome Completed NCT01452789 Phase 3 sublingual buprenorphine;oral morphine
7 Fetal and Infant Effects of Maternal Buprenorphine Treatment Completed NCT01561079 Phase 2, Phase 3 Buprenorphine
8 Maternal Acupuncture for Substance Abuse Completed NCT00225316 Phase 3
9 How to Treat Opiate Withdrawal in Neonates Completed NCT02810782 Phase 3 Phenobarbital;Chlorpromazine;Morphine
10 Tobacco Use in Opioid Agonist Treated Pregnant Women Completed NCT00497068 Phase 2, Phase 3
11 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
12 Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain Recruiting NCT03396588 Phase 3 Clonidine;Morphine
13 Improving Outcomes in Neonatal Abstinence Syndrome Active, not recruiting NCT01958476 Phase 3 Neonatal Morphine Solution;Methadone;Phenobarbital
14 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels Enrolling by invitation NCT03097484 Phase 3 lavender and chamomile essential oils
15 Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants Terminated NCT01360450 Phase 2, Phase 3 Clonidine HCL;saline
16 Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome Completed NCT00510016 Phase 2 Clonidine HCL
17 RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants Completed NCT02178189 Phase 2
18 The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1 Completed NCT00218621 Phase 2
19 How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women Completed NCT01801475 Phase 1, Phase 2 Ondansetron
20 Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women Recruiting NCT01965704 Phase 2 Ondansetron;Placebo
21 Methadone Demonstration Project Recruiting NCT03134703 Phase 2 Methadone;Morphine
22 Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study Recruiting NCT02249026 Phase 1, Phase 2 BZDs + opiate exposure treated with BPN;Opiates exposure treated with BPN
23 Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS) Enrolling by invitation NCT01708707 Phase 2 Buprenorphine;Morphine Sulfate
24 Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome Not yet recruiting NCT02872077 Phase 1, Phase 2
25 Maternal Buprenorphine-naloxone Treatment and the Infant Not yet recruiting NCT03291847 Phase 2 Buprenorphine Naloxone;Methadone
26 Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines Completed NCT01671410 Phase 1 oral morphine;sublingual buprenorphine
27 The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome Completed NCT01754324 Phase 1 Methadone
28 Buprenorphine for the Treatment of Neonatal Abstinence Syndrome Completed NCT00521248 Phase 1 buprenorphine;Oral morphine solution
29 Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies Unknown status NCT02062151
30 Vagal Tone and Neonatal Abstinence Syndrome Completed NCT00496951
31 Weighted Blankets With Infants With NAS Completed NCT03113656
32 Interest of Concentrations in Meconium of Buprenorphine and Methadone as a Prognostic Factor of NAS Outcome Completed NCT03334981
33 Buprenorphine Dose Adjustments and Gestational Age Completed NCT03028883
34 Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers Completed NCT01889121
35 RESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure Completed NCT02334111
36 Fetal Neurobehavior in Poly-drug Dependent Women Completed NCT00653692
37 Fetal Neurobehavioral Development in Methadone Maintained Pregnancies Completed NCT00067184
38 The Effect of Fetal Gender on Maternal Substance Abuse Treatment Completed NCT00882648
39 Conflict Between Maternal Autonomy and Child Health in Substance-use Completed NCT02797990
40 Opioid Dependence Treatment Therapies in Pregnancy Recruiting NCT03098407 Buprenorphine;Methadone
41 Donor Human Milk in Neonatal Abstinence Syndrome Active, not recruiting NCT02182973
42 Physiology and Therapeutic Management of Neonatal Abstinence Syndrome Enrolling by invitation NCT02768844
43 Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome Enrolling by invitation NCT02801331
44 Clonidine for Neonatal Abstinence Syndrome Study Terminated NCT01175668 Clonidine;Phenobarbital

Search NIH Clinical Center for Neonatal Abstinence Syndrome

Cochrane evidence based reviews: neonatal abstinence syndrome

Genetic Tests for Neonatal Abstinence Syndrome

Anatomical Context for Neonatal Abstinence Syndrome

MalaCards organs/tissues related to Neonatal Abstinence Syndrome:

38
Brain, Breast, Heart

Publications for Neonatal Abstinence Syndrome

Articles related to Neonatal Abstinence Syndrome:

(show top 50) (show all 258)
# Title Authors Year
1
Torticollis in Infants with a History of Neonatal Abstinence Syndrome. ( 29395169 )
2018
2
Nonpharmacological management of neonatal abstinence syndrome: a review of the literature. ( 29207895 )
2018
3
Mental Health of Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Opioid Exposure. ( 29417369 )
2018
4
Neonatal Abstinence Syndrome: Exploring Nurses' Attitudes, Knowledge, and Practice. ( 29360671 )
2018
5
Association of Rooming-in With Outcomes for Neonatal Abstinence Syndrome: A Systematic Review and Meta-analysis. ( 29404599 )
2018
6
Safety of Reiki Therapy for Newborns at Risk for Neonatal Abstinence Syndrome. ( 29315084 )
2018
7
The Role of Preterm Birth in the Association Between Opioid Maintenance Therapy and Neonatal Abstinence Syndrome. ( 29372750 )
2018
8
Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. ( 29266062 )
2018
9
Hospital Variation in Neonatal Abstinence Syndrome Incidence, Treatment Modalities, Resource Use, and Costs Across Pediatric Hospitals in the United States, 2013 to 2016. ( 29263122 )
2018
10
Neonatal Abstinence Syndrome and the Pediatric Hospitalist: 5 Years Later. ( 29263123 )
2018
11
A Novel Approach to Assessing Infants With Neonatal Abstinence Syndrome. ( 29263121 )
2018
12
Treating Neonatal Abstinence Syndrome in a Rural Hospital: Lessons Learned. ( 29428413 )
2018
13
A Quality Improvement Initiative to Increase Scoring Consistency and Accuracy of the Finnegan Tool: Challenges in Obtaining Reliable Assessments of Drug Withdrawal in Neonatal Abstinence Syndrome. ( 29373349 )
2018
14
Feeding Infants with Neonatal Abstinence Syndrome: Finding the Sweet Spot. ( 29436353 )
2018
15
Neonatal abstinence syndrome: an update. ( 29346142 )
2018
16
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28877015 )
2017
17
Neonatal Abstinence Syndrome Better Treated With Buprenorphine. ( 28655009 )
2017
18
The Genomics of Neonatal Abstinence Syndrome. ( 28879171 )
2017
19
A management strategy that reduces NICU admissions and decreases charges from the front line of the neonatal abstinence syndrome epidemic. ( 28682317 )
2017
20
Neonatal Abstinence Syndrome Management: A Review of Recent Evidence. ( 28814260 )
2017
21
Opioid Use and Abuse and Neonatal Abstinence Syndrome. ( 28726245 )
2017
22
The economic burden of neonatal abstinence syndrome in the United States. ( 28612362 )
2017
23
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28880503 )
2017
24
Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. ( 28594753 )
2017
25
Neonatal abstinence syndrome and early childhood morbidity and mortality in Washington state: a retrospective cohort study. ( 28682319 )
2017
26
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28880502 )
2017
27
The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care. ( 28073819 )
2017
28
In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature. ( 28543284 )
2017
29
Pharmacists' and prescribers' neonatal abstinence syndrome (NAS) prevention behaviors: a preliminary analysis. ( 29209864 )
2017
30
An Initiative to Improve the Quality of Care of Infants With Neonatal Abstinence Syndrome. ( 28562267 )
2017
31
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28877016 )
2017
32
The Effect of Morphine Dosing on Length of Stay in Neonatal Abstinence Syndrome - An Alternative Viewpoint. ( 28949409 )
2017
33
Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity. ( 27983768 )
2017
34
Evaluation of the Effectiveness of Two Morphine Protocols to Treat Neonatal Abstinence Syndrome in a Level II Nursery in a Community Hospital. ( 28594450 )
2017
35
Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. ( 28685864 )
2017
36
Neonatal Abstinence Syndrome and Ethical Approaches to the Identification of Pregnant Women Who Use Drugs. ( 27926654 )
2017
37
Re: Neonatal Abstinence Syndrome and High School Performance. ( 28814556 )
2017
38
Opioid Neonatal Abstinence Syndrome: An Overview. ( 29285767 )
2017
39
Neonatal abstinence syndrome: Neurobehavior at 6 weeks of age in infants with or without pharmacological treatment for withdrawal. ( 28561904 )
2017
40
Re: Neonatal Abstinence Syndrome and High School Performance. ( 28814555 )
2017
41
Neonatal Abstinence Syndrome: Twins Case Series. ( 29312901 )
2017
42
Rates of Neonatal Abstinence Syndrome Amid Efforts to Combat the Opioid Abuse Epidemic. ( 27669331 )
2016
43
Neonatal Abstinence Syndrome. ( 28002715 )
2016
44
The relationship between gestational age and the severity of neonatal abstinence syndrome. ( 27886650 )
2016
45
Active Somatic and Psychic Ear Acupuncture Points in Newborn Infants with Neonatal Abstinence Syndrome. ( 27486672 )
2016
46
Neonatal Abstinence Syndrome Following Tianeptine Dependence During Pregnancy. ( 26659818 )
2016
47
NEONATAL ABSTINENCE SYNDROME AND THE ATTACHMENT RELATIONSHIP. ( 29251895 )
2016
48
Nonpharmacologic Management of Neonatal Abstinence Syndrome: An Integrative Review. ( 27636695 )
2016
49
Neonatal abstinence syndrome and the gastrointestinal tract. ( 27876117 )
2016
50
Early Treatment for Neonatal Abstinence Syndrome: A Palliative Approach. ( 27907936 )
2016

Variations for Neonatal Abstinence Syndrome

Expression for Neonatal Abstinence Syndrome

Search GEO for disease gene expression data for Neonatal Abstinence Syndrome.

Pathways for Neonatal Abstinence Syndrome

Pathways related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.68 OPRD1 OPRM1

GO Terms for Neonatal Abstinence Syndrome

Cellular components related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.43 COMT OPRK1 OPRM1
2 perikaryon GO:0043204 9.37 OPRK1 OPRM1
3 neuron projection GO:0043005 9.33 OPRD1 OPRK1 OPRM1
4 axon terminus GO:0043679 9.32 OPRD1 OPRK1
5 intrinsic component of plasma membrane GO:0031226 8.96 LY96 OPRD1
6 dendrite membrane GO:0032590 8.62 OPRD1 OPRM1

Biological processes related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.69 OPRD1 OPRK1 OPRM1
2 response to lipopolysaccharide GO:0032496 9.67 COMT LY96 OPRM1
3 neuropeptide signaling pathway GO:0007218 9.61 OPRD1 OPRK1 OPRM1
4 cellular response to lipopolysaccharide GO:0071222 9.59 LY96 OPRK1
5 response to ethanol GO:0045471 9.58 OPRK1 OPRM1
6 locomotory behavior GO:0007626 9.58 OPRK1 OPRM1
7 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.58 OPRD1 OPRK1 OPRM1
8 response to estrogen GO:0043627 9.57 COMT OPRK1
9 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.56 OPRD1 OPRM1
10 response to radiation GO:0009314 9.55 OPRK1 OPRM1
11 response to cocaine GO:0042220 9.54 OPRK1 OPRM1
12 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.54 OPRD1 OPRK1 OPRM1
13 response to morphine GO:0043278 9.52 OPRK1 OPRM1
14 sensory perception of pain GO:0019233 9.5 OPRD1 OPRK1 OPRM1
15 estrous cycle GO:0044849 9.48 OPRK1 OPRM1
16 sensory perception GO:0007600 9.46 OPRK1 OPRM1
17 eating behavior GO:0042755 9.33 OPRD1 OPRK1 OPRM1
18 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.26 OPRK1 OPRM1
19 opioid receptor signaling pathway GO:0038003 9.13 OPRD1 OPRK1 OPRM1
20 regulation of sensory perception of pain GO:0051930 8.92 COMT OPRD1 OPRK1 OPRM1

Molecular functions related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide binding GO:0042923 9.13 OPRD1 OPRK1 OPRM1
2 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Neonatal Abstinence Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....